FDA and American Cancer Society address cancer burden and testing options through regulatory approvals and guidelines.
3 reports, 3 independent
Updated Aug 18
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 4
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA and American Cancer Society address cancer burden and testing options through regulatory approvals and guidelines.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Daniel Lin chairs guideline amendments for US care, and the American Cancer Society provides current cancer statistics for the US population.Sub-event
- A blood-based test, involving entities like Abbott and Freenome, has been submitted for commercialization review and included in ACS guidelines.Sub-event
- American Cancer Society recommends new blood-based screening tests for adults.Sub-event
Regulatory approvals and guidelines address cancer burden in the country.1 source
Keep exploring
The entities involved
- FDA
-
American Cancer Society
health organization seeking to cure and treat cancer
Related events
- The American Cancer Society and Preventive Services Task Force set recommended guidelines for cancer screenings.
- Experimental therapies require approval from the FDA.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA guidance changes affect biosimilar approval, impacting Coherus Oncology, Inc.
- FDA sets standards for e-cigarette product approval.